PURPOSE: To evaluate variability of a simplified method for measuring semiquantitative DCE-MRI parameters in patients with cancer and to explore effects of treatment with a putative anti-angiogenic compound. MATERIALS AND METHODS: A total of 19 patients enrolled on treatment trials with the putative anti-angiogenic agent SU5416 underwent contrast enhanced examinations, and 11 had a second examination eight weeks post therapy. Contrast media concentration as a function of time was calculated using changes in signal and literature baseline T(1) values in normal muscle or liver reference tissue. Semiquantitative DCE-MRI parameters, including the area under the contrast concentration vs. time curve (AUC), were calculated for regions-of-interest in normal liver and muscle, and in tumors. RESULTS: The coefficients of variation for pretherapy parameters in normal tissue were 11% to 37%. No significant changes were detected in normal liver over two months of therapy. In tumors and muscle, a significant decrease in the AUC and maximum contrast concentration was observed. CONCLUSION: Variability of semiquantitative DCE-MRI parameters utilizing a method based on known T(1) values in a reference tissue is low enough to detect changes in tumors during therapy. Use of this method as a pharmacodynamic marker should be further investigated. Copyright 2004 Wiley-Liss, Inc.
PURPOSE: To evaluate variability of a simplified method for measuring semiquantitative DCE-MRI parameters in patients with cancer and to explore effects of treatment with a putative anti-angiogenic compound. MATERIALS AND METHODS: A total of 19 patients enrolled on treatment trials with the putative anti-angiogenic agent SU5416 underwent contrast enhanced examinations, and 11 had a second examination eight weeks post therapy. Contrast media concentration as a function of time was calculated using changes in signal and literature baseline T(1) values in normal muscle or liver reference tissue. Semiquantitative DCE-MRI parameters, including the area under the contrast concentration vs. time curve (AUC), were calculated for regions-of-interest in normal liver and muscle, and in tumors. RESULTS: The coefficients of variation for pretherapy parameters in normal tissue were 11% to 37%. No significant changes were detected in normal liver over two months of therapy. In tumors and muscle, a significant decrease in the AUC and maximum contrast concentration was observed. CONCLUSION: Variability of semiquantitative DCE-MRI parameters utilizing a method based on known T(1) values in a reference tissue is low enough to detect changes in tumors during therapy. Use of this method as a pharmacodynamic marker should be further investigated. Copyright 2004 Wiley-Liss, Inc.
Authors: James P B O'Connor; Alan Jackson; Geoff J M Parker; Caleb Roberts; Gordon C Jayson Journal: Nat Rev Clin Oncol Date: 2012-02-14 Impact factor: 66.675
Authors: Nathaniel K Chan; Andre Obenaus; Annie Tan; Naoaki Sakata; John Mace; Ricardo Peverini; Richard Chinnock; Lawrence C Sowers; Eba Hathout Journal: Islets Date: 2009-11 Impact factor: 2.694
Authors: Eba Hathout; Lawrence Sowers; Rong Wang; Annie Tan; John Mace; Ricardo Peverini; Richard Chinnock; Andre Obenaus Journal: Transpl Int Date: 2007-09-10 Impact factor: 3.782
Authors: Randy F Sweis; Milica Medved; Shannon Towey; Gregory S Karczmar; Aytekin Oto; Russell Z Szmulewitz; Peter H O'Donnell; Paul Fishkin; Theodore Karrison; Walter M Stadler Journal: Clin Genitourin Cancer Date: 2016-08-17 Impact factor: 2.872
Authors: Cheng Yang; Gregory S Karczmar; Milica Medved; Aytekin Oto; Marta Zamora; Walter M Stadler Journal: Magn Reson Med Date: 2009-04 Impact factor: 4.668